Royal Bank of Canada Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $136.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $143.00 to $136.00 in a report released on Thursday morning, Benzinga reports. The firm currently has a sector perform rating on the stock. Several other equities analysts also recently issued reports on the company. StockNews.com upgraded Neurocrine Biosciences […]
More Stories
Impax Asset Management Group (LON:IPX) Sets New 12-Month Low – Here’s What Happened
Impax Asset Management Group Plc (LON:IPX – Get Free Report)’s share price hit a new 52-week low during trading on...
Biglari (NYSE:BH.A) Shares Down 7% – Time to Sell?
Biglari Holdings Inc (NYSE:BH.A – Get Free Report)’s share price dropped 7% on Tuesday . The company traded as low...
Claros Mortgage Trust (NYSE:CMTG) Reaches New 52-Week Low – Here’s Why
Shares of Claros Mortgage Trust, Inc. (NYSE:CMTG – Get Free Report) reached a new 52-week low during trading on Tuesday...
Roku (NASDAQ:ROKU) Trading Down 0.4% – Time to Sell?
Roku, Inc. (NASDAQ:ROKU – Get Free Report) fell 0.4% on Tuesday . The stock traded as low as $78.01 and...
Fast Retailing (OTCMKTS:FRCOY) Announces Quarterly Earnings Results
Fast Retailing (OTCMKTS:FRCOY – Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.29 earnings per...
Trigon Metals (CVE:TM) Sets New 12-Month Low – Here’s What Happened
Trigon Metals Inc. (CVE:TM – Get Free Report)’s share price hit a new 52-week low on Thursday . The company...